Daré Bioscience Secures $2M NIH Grant for HPV Treatment Development

Event summary

  • Daré Bioscience received a $1M second tranche of NIH funding, bringing total NIH support for DARE-HPV to $2M.
  • The Phase 2 clinical trial for DARE-HPV, targeting persistent high-risk HPV infection, began on May 18, 2026.
  • DARE-HPV is a novel investigational treatment with no FDA-approved alternatives currently available.
  • The NIAID grant supports non-clinical activities, while ARPA-H funds the Phase 2 study under a $10M contract.

The big picture

Daré Bioscience's NIH funding and Phase 2 trial initiation highlight the critical unmet need for treatments targeting persistent high-risk HPV infection, a precursor to cervical cancer. The company's strategy of leveraging government grants and contracts to advance its pipeline underscores the challenges of funding women's health innovations. With an estimated 6 million women in the U.S. affected annually, DARE-HPV's potential market opportunity is significant if it achieves regulatory approval.

What we're watching

Clinical Trial Outcomes
The success of the Phase 2 trial will determine DARE-HPV's potential as the first FDA-approved treatment for high-risk HPV infection.
Regulatory Pathway
Whether DARE-HPV can navigate the FDA's 505(b)(2) pathway efficiently will impact its approval timeline and market entry.
Funding Sustainability
The pace at which Daré secures additional non-dilutive funding will influence its ability to advance DARE-HPV through later-stage trials.

Related topics

Biotechnology